Fundsmith Appoints FundRock for Distribution of Fundsmith SICAV
28.11.2022 11:00:00 EET | Business Wire | Press release
FundRock Management Company, a leading European third-party UCITS Management Company (“ManCo”) and Alternative Investment Fund Manager (“AIFM”), announces the expansion of its relationship with leading fund management company Fundsmith LLP, to now include distribution services.
FundRock enables clients to streamline their operations in a cost-effective manner by offering third-party ManCo and fund distribution services under one roof, complemented by a wide range of fund administration, middle office, banking, depositary and custody services delivered through parent company Apex Group.
In addition to existing ManCo services, FundRock Distribution S.A. will now provide distribution services, enabling Fundsmith LLP to distribute its funds in the EU.
FundRock’s established network of more than 200 experts in key jurisdictions including Luxembourg, the United Kingdom, Ireland, Netherlands, France, Italy, Switzerland, Germany, Abu Dhabi and Singapore delivers significant time, resource and cost benefits.
Arnaud Gérard, CFA, Head of Distribution at FundRock, commented: “FundRock Distribution offers a powerful solution for asset managers, providing local knowledge combined with an established network of contacts, enabling our clients to focus on their core business. We look forward to supporting Fundsmith to distribute their funds more efficiently and effectively in EU markets, while ensuring the highest standards of governance and regulatory compliance.”
Mark Laurence, COO at Fundsmith, commented: “We are delighted to extend our existing relationship with FundRock to help manage our post Brexit EU distribution. In particular it will allow us to target the Italian market through the services of incoming FundRock Sales Director, Giuseppe Bellavia, who joins from Allianz Global Life and has been appointed as Sales Director of FundRock to lead distribution for Fundsmith in Italy.”
About Fundsmith SICAV
Fundsmith SICAV is the umbrella fund for Fundsmith Equity Fund and Fundsmith Sustainable Equity Fund.
Fundsmith Equity Fund, a sub-fund of the Fundsmith SICAV, is managed with exactly the same process as the same-named, largest active equity fund in the UK. Fundsmith Equity Fund offers investors a high quality, concentrated portfolio of 20-30 resilient, global growth companies which are held for the long term.
The Fundsmith Equity Fund takes sustainability risk and ESG characteristics into account as part of its selection process. In that respect, the Fundsmith Equity Fund promotes environmental and/or social characteristics within the meaning of Article 8 of SFDR. Fundsmith Equity Fund is rated Gold by Morningstar and has a four crown FE fundinfo rating.
Fundsmith Sustainable Equity Fund is also an Article 8 fund and it follows the same strategy as Fundsmith Equity Fund but with an important difference, namely the following sectoral exclusions that are stipulated in the fund prospectus:
- No Aerospace and Defence
- No Brewers, Distillers and Vintners
- No Casinos and Gaming
- No Gas and Electric Utilities
- No Metals and Mining
- No Oil, Gas and Consumable Fuels
- No Pornography
- No Tobacco
In addition, investments are screened for sustainability in the widest sense, taking account not only the companies’ handling of environmental, social and governance policies and practices but also their policies and practices on research and development, new product innovation, dividend policy and the adequacy of capital investment. Fundsmith Sustainable Equity Fund has a LuxFLAG ESG Label, which has the primary objective to reassure investors that the investment product incorporates ESG criteria throughout the entire investment process while screening 100% of their invested portfolio according to one of the ESG strategies and standards recognised by LuxFLAG.
Terry Smith, Portfolio Manager of Fundsmith Equity Fund and Fundsmith Sustainable Equity Fund, commented: “We will only invest in companies that have attractive valuations, high barriers to entry and are extremely resilient. We like companies with a business advantage that is hard to replicate and which are resilient to change, particularly to technological change. The kind of intangible assets we seek are brand names, high market shares, patents, licenses, distribution networks, installed bases and client relationships. We especially like companies that produce goods which are consumed at short and regular intervals and which sell directly to consumers. A company that sells many small items every day is better able to earn more consistent returns over time than a company whose business is cyclical, like a steel manufacturer, or “lumpy”, like a property developer or which sells items that are expensive and durable like a motor manufacturer."
Terry Smith, founder of Fundsmith, is the portfolio manager of Fundsmith Equity Fund and Fundsmith Sustainable Equity Fund. Terry is well-known for his straight talking and clear three step investment strategy that seeks to buy good companies, not overpay and do nothing.
Since inception of the Fundsmith Equity Fund in the UK in 2010 to the end of October 2022, the fund’s assets have grown to over £22 billion and it has delivered a total return of over 460% or 15.5% annualised, net of fees.
Fundsmith Equity Fund, a sub-fund of the Fundsmith SICAV, has growth its assets under management to over €8bn and it has delivered a total return since its inception in 2011 of over 399.7% or 15.8% annualised, net of fees.
Terry Smith added: “We have grown Fundsmith Equity Fund into the UK’s largest active equity fund, built on our successful strategy of investing in a small number of high quality companies that can be held for the long term. While our strategy is simple, it requires rigorous analysis and strict discipline to deliver superior returns over the long-term at a reasonable cost.
“We established our SICAV in Luxembourg in 2011 and are pleased to have extended our relationship with FundRock so we can actively distribute across the EU, in particular targeting Italy with the expertise of FundRock Sales Director Giuseppe Bellavia.”
FUND FACTS
MINIMUM INVESTMENT: €2,000
CHARGES:
No initial charge
No performance fee
No redemption fees
Annual Management Fee 1%
Estimated OCF – Fundsmith Equity Fund 1.09%
Estimated OCF – Fundsmith Sustainable Equity Fund 1.12%
UNITS: Income or Accumulation
-Ends-
About FundRock Distribution S.A.
FundRock Distribution S.A., a subsidiary of the Apex Group, is authorised by the Luxembourg regulator, the CSSF, to act as investment adviser and distributor of shares/ units of funds. Under this MiFID license, FundRock is able to act as global distributor/sub-distributor of the funds managed by our affiliates. They leverage their free provision of services (passport) through the European Union to offer a long term and stable solution to our clients. FundRock offers a more flexible and economical go to market solution including, streamlined access to fund platforms, fund distribution support and direct representation.
FundRock Distribution S.A. is a subsidiary of FundRock Management Company S.A., a leading independent UCITS management company and AIFM investment fund manager. As of September 2022, FundRock oversees more than 500 funds with a total of €116 billion in assets under management, including Italian domiciled funds. The FundRock group has more than 200 employees in eight countries including Luxembourg, United Kingdom, Ireland, France, Switzerland, Abu Dhabi and Singapore.
About Fundsmith
Fundsmith is focused on delivering superior investment performance at a reasonable cost. It was established to be different from its peers so as to achieve a different result in line with Sir John Templeton’s axiom that “If you want to have a better performance than the crowd, you must do things differently from the crowd.” The rigorous research process of Fundsmith is central to what we do. We apply exacting standards to potential investments to produce a portfolio of resilient businesses with excellent performance. Minimising the costs we incur on behalf of our customers in implementing our strategy also sits at the heart of our philosophy.
Fundsmith was established in 2010 by Terry Smith. The business is owned and controlled by its partners, who have worked closely together over many years, and is headquartered in London with offices in Mauritius and Connecticut, USA. It is structured to survive Terry Smith’s demise and continue with the same investment philosophy. All partners of the firm have a significant coinvestment in our Funds delivering a clear alignment of interest. Ancillary activities are outsourced to some of the world's leading providers in order to deliver high quality operations whilst allowing the Fundsmith team to focus on the investment analysis and portfolio management and customer care.
www.fundsmith.eu
www.fundsmith.eu/fsef/
Fundsmith SICAV is an investment company organised under the laws of the Grand Duchy of Luxembourg as a societé d’investissement à capital variable, is governed by Part I of the UCI Law and qualifies as a UCITS.
Before making any investment decisions, please refer to the Prospectus and Key Investor Information Document (KIID)s in English, Danish, Dutch, French, German, Italian, Norwegian, Portuguese, Spanish and Swedish, available on the Fundsmith SICAV website https://www.fundsmith.eu/documents/.
A summary of your investor rights can be found in English here, https://www.fundsmith.eu/investor-rights. Past performance is not necessarily a guide to future performance. The value of investments and the income from them may fall as well as rise and be affected by changes in exchange rates, and you may not get back the amount of your original investment.
Issued 1 Sep 2022 within Europe (ex-Switzerland) by FundRock Distribution S.A. (“FRD”) the EU distributor for Fundsmith SICAV. FRD is a public limited company, incorporated under the laws of the Grand Duchy of Luxembourg, registered office at 9A, rue Gabriel Lippmann, L-5365 Munsbach, Luxembourg, and registered with the Luxembourg trade and companies register under number B253257. FRD is authorized as distributor of shares/units of UCIs without making or accepting payments (within the meaning of Article 24-7 of the 1993 Law), as updated from time to time. FRD is authorised and regulated by the Commission de Surveillance du Secteur Financier (CSSF).
Please note that FundRock Management Company S.A. may decide to terminate the arrangements made for the marketing of the Fund under the denotification process in new Cross-border Distribution Directive (Directive (EU) 2019/1160).
This is a marketing communication.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221122005425/en/
Contact information
For further information please contact:
Fundsmith:
Charlotte Balbirnie
+44 (0)7989 528421
CBalbirnie@keplercomms.com
Caroline Villiers
+44 (0)7808 585184
CVilliers@keplercomms.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
